Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

PURPOSE: Keyhole limpet hemocyanin (KLH) attracts biomedical interest because of its remarkable immunostimulatory properties. Currently, KLH is used as vaccine adjuvant, carrier protein for haptens and as local treatment for bladder cancer. Since a quantitative human anti-KLH assay is lacking, it ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Aarntzen, Erik H. J. G., de Vries, I. Jolanda M., Göertz, Joop H., Beldhuis-Valkis, Marjo, Brouwers, Huberdina M. L. M., van de Rakt, Mandy W. M. M., van der Molen, Renate G., Punt, Cornelis J. A., Adema, Gosse J., Tacken, Paul J., Joosten, Irma, Jacobs, Joannes F. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493659/
https://www.ncbi.nlm.nih.gov/pubmed/22527252
http://dx.doi.org/10.1007/s00262-012-1263-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493659/
https://www.ncbi.nlm.nih.gov/pubmed/22527252
http://dx.doi.org/10.1007/s00262-012-1263-z

Ejemplares similares